XML 95 R61.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) $ in Thousands | Dec. 31, 2019 USD ($) $ / shares | Dec. 31, 2018 USD ($) $ / shares | Dec. 31, 2017 USD ($)
--- | --- | --- | ---
Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | $ 3,186 | $ 3,814 |
Minimum | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | $ / shares | 6.76 | 6.76 |
Minimum | Volatility | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.2893 | 0.4653 |
Minimum | Risk free interest rate | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.0019 | 0.0244 |
Minimum | Expected life | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.01 | 0.01 |
Maximum | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | $ / shares | 30.86 | 30.86 |
Maximum | Volatility | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.5959 |
Maximum | Risk free interest rate | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.0263 |
Maximum | Expected life | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Measurement input | 1.01 | 1.01 |
Significant unobservable inputs (level 3) | Stock Appreciation Rights (SARs) |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | $ 3,186 | $ 3,814 | $ 1,665
Significant unobservable inputs (level 3) | Agilis |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | 65,800 |  |
Liability, Development and Regulatory Milestone | Agilis |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | 290,500 | 257,040 |
Liability, Development and Regulatory Milestone | Agilis | Minimum | Potential development and regulatory milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone |  | $ 0 |
Liability, Development and Regulatory Milestone | Agilis | Minimum | Potential net sales milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone | $ 0 |  |
Liability, Development and Regulatory Milestone | Agilis | Minimum | Probabilities of success | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.25 | 0.25 |
Liability, Development and Regulatory Milestone | Agilis | Minimum | Potential percentage of net sales for royalties | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.02 |  |
Liability, Development and Regulatory Milestone | Agilis | Minimum | Discount rate | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.058 |
Liability, Development and Regulatory Milestone | Agilis | Maximum | Potential development and regulatory milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone |  | $ 555,000 |
Liability, Development and Regulatory Milestone | Agilis | Maximum | Potential net sales milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone | $ 150,000 |  |
Liability, Development and Regulatory Milestone | Agilis | Maximum | Probabilities of success | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.89 | 0.94 |
Liability, Development and Regulatory Milestone | Agilis | Maximum | Potential percentage of net sales for royalties | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.06 |  |
Liability, Development and Regulatory Milestone | Agilis | Maximum | Discount rate | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.080 |
Liability, Development and Regulatory Milestone | Significant unobservable inputs (level 3) | BioElectron | Commitments |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | $ 290,500 | $ 257,040 | 0
Liability, Net Sales Milestones and Royalties | Agilis |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | $ 65,800 | $ 53,200 |
Liability, Net Sales Milestones and Royalties | Agilis | Discount rate | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.145 | 0.140 |
Liability, Net Sales Milestones and Royalties | Agilis | Minimum | Potential development and regulatory milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone | $ 0 |  |
Liability, Net Sales Milestones and Royalties | Agilis | Minimum | Potential net sales milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone |  | $ 0 |
Liability, Net Sales Milestones and Royalties | Agilis | Minimum | Probabilities of success | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.25 | 0.25 |
Liability, Net Sales Milestones and Royalties | Agilis | Minimum | Potential percentage of net sales for royalties | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.02 |
Liability, Net Sales Milestones and Royalties | Agilis | Minimum | Discount rate | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.022 |  |
Liability, Net Sales Milestones and Royalties | Agilis | Maximum | Potential development and regulatory milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone | $ 555,000 |  |
Liability, Net Sales Milestones and Royalties | Agilis | Maximum | Potential net sales milestones | Commitments |  |  |
Fair value of warrant liability |  |  |
Milestone |  | $ 150,000 |
Liability, Net Sales Milestones and Royalties | Agilis | Maximum | Probabilities of success | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.94 | 0.89 |
Liability, Net Sales Milestones and Royalties | Agilis | Maximum | Potential percentage of net sales for royalties | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input |  | 0.06 |
Liability, Net Sales Milestones and Royalties | Agilis | Maximum | Discount rate | Commitments |  |  |
Fair value of warrant liability |  |  |
Measurement input | 0.047 |  |
Liability, Net Sales Milestones and Royalties | Significant unobservable inputs (level 3) | BioElectron |  |  |
Fair value of warrant liability |  |  |
Contingent consideration payable- net sales milestones and royalties | $ 65,800 | $ 53,200 | $ 0

X
- Definition Alternative Investment, Milestone + References No definition available. + Details
Name: | ptct_AlternativeInvestmentMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure alternative investment. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=ptct_PercentageofSalesforRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |